Tresiba Bolsters Novo Nordisk’s Japan Position
This article was originally published in PharmAsia News
Executive Summary
Novo Nordisk’s diabetes market share in Japan is regaining ground as newer products Tresiba and Victoza carve out niches in the highly competitive sector.